The Crystec team has been in Nanjing, China to attend DPI 2025 hosted by DFE Pharma. This was an incredibly rewarding event with two days of thoughtful talks on Dry Powder Inhaler development. There were a number of interesting subjects, from Biologics & mRNA in inhalation to regulatory challenges.
Crystec COO Qun Shao had the opportunity to speak about Crystec’s novel mSAS® technology and our ‘fast to clinic’ platform partnership with Intertek, which helps to support pharmaceutical clients with rapid DPI development, from the initial formulation concept to GMP clinical manufacturing, in less than half the time typically required.
If you didn’t manage to meet CrystecPharma at DPI please visit us online or schedule a meeting at https://crystecpharma.com/